Pay in 4 interest-free payments of $5.05 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
The approval is backed by results from the Phase IIb/III QUASAR study, in which participants given 200 mg of Tremfya every four weeks saw clinical remission at 44 weeks, compared with 19% in the placebo group
Current and emerging gonadotropin-releasing hormone (GnRH) antagonists for the treatment of prostate cancer
Features include Noom 360 Body Scan, Noom Success Kit, Noom Vibe, and Noom Mood
Regulatory Expectations for Peptide Sequencing in Late-Stage Filings Regulatory authorities such as the FDA, EMA, and PMDA require comprehensive structural characterization of therapeutic peptides prior to approval
US$ 27.30
US$ 28.51
US$ 26.92
US$ 26.30
US$ 25.01
US$ 28.72
